HONG KONG – South Korea's Celltrion Inc. will be the first foreign company in China to initiate clinical trials of an antibody biosimilar. The company recently received the go-ahead from the CFDA for a trial testing Remsima (infliximab), based on an application submitted two years ago under the agency's IND program. Read More
SHANGHAI – The hot topic at the 9th DIA China annual meeting was China's proposed entry into the ICH, a global body that facilitates the harmonizing of drug regulations across countries. Acceptance into the ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) would be a major milestone for China's regulatory reform efforts and give the drug industry a leg up on the global stage. Read More
TEL AVIV, Israel – Israel has plenty of innovators and researchers and is pumping out new innovative ideas and research at record speed, but a lack of infrastructure may be holding the industry back and preventing the emergence of companies of global stature. Read More
TEL AVIV, Israel – A presentation in early June to the American Society of Clinical Oncology (ASCO) will mark yet another small step in Israeli firm Compugen Ltd.'s ongoing effort to transform itself from a computational drug target discovery company into a preclinical or even clinical-stage drug company. Read More
TEL AVIV, Israel – One of the most visible contingents of investors and industry people during the recent MIXiii Biomed conference came from China. Two large delegations brought in more than 170 participants, a Chinese researcher gave one of the keynotes on aging and for some delegates there was simultaneous translation in Mandarin. Read More
Japanese researchers have screened existing drugs for potential to treat amyotrophic lateral sclerosis (ALS) using neurons developed from induced pluripotent stem (iPS) cells of a patient with an ALS gene mutation, thereby identifying a potential new target pathway for drugs against the currently incurable disease. Read More
HONG KONG – Cancer in China is on the rise, and so is the demand for innovative cancer treatments. Local and multinational drugmakers are racing to tap into the growing need for new and effective treatments. Read More
